Indaptus Therapeutics (INDP) AI Stock Analysis

• Market Cap: $7.20M
• Dividend Yield: N/A
• Average Volume (3M): 45.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: N/A
• EPS Growth: 11.97%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 16,034,445
• 10 Day Avg. Volume: 52,383
• 30 Day Avg. Volume: 45,196
• PEG Ratio: -0.05
• Price to Book (P/B): 2.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.54
• Enterprise Value/Market Cap: 0.47
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: $2.00
• Price Target Upside: 344.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company's valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.

Positive Factors

Clinical Trials

The Safety Review Committee cleared the study for unrestricted enrollment, indicating good safety signals and allowing for increased enrollment.

Partnerships

Indaptus signed a clinical supply agreement with BeiGene for its PD-1, tislelizumab, which could enhance the study by potentially combining treatments.

Safety Profile

The safety and pharmacokinetic (PK) profile for Decoy20 has been positive and demonstrated broad immune responses.

Negative Factors

Capital Requirements

The company needs to raise additional capital in the near-term.

Financial Position

Indaptus reported a net loss of ($4.5M) and ended the period with $3.9M in cash on the balance sheet.

Indaptus Therapeutics Business Overview & Revenue Model

Company Description

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

How the Company Makes Money

Indaptus Therapeutics primarily makes money through the development and potential commercialization of its therapeutic candidates. The company's revenue model is centered around advancing its drug candidates through clinical trials, obtaining regulatory approvals, and eventually bringing these drugs to market. Key revenue streams include potential milestone payments and royalties from licensing agreements and strategic partnerships with larger pharmaceutical companies. These collaborations may provide funding for research and development activities, as well as access to distribution networks upon successful drug commercialization. Additionally, Indaptus may seek to secure grants and funding from governmental and non-governmental organizations to support its research initiatives.

Indaptus Therapeutics Financial Statement Overview

Summary

Indaptus Therapeutics faces significant financial challenges, with no revenue generation and consistent net losses impacting its income statement. The balance sheet shows declining equity and negative returns, reflecting financial instability. Cash flow statements indicate liquidity issues, as the company struggles to generate positive cash flow. These factors collectively highlight a high-risk financial position for the company.

Income Statement

Indaptus Therapeutics has consistently reported zero revenue over the years, which is a major concern for financial health. The company has also experienced significant net losses each year, with no gross profit margins to report. The negative EBIT and EBITDA margins indicate ongoing operational challenges, and the lack of revenue growth further reflects its struggles in generating income.

Balance Sheet

The balance sheet reveals a relatively low level of debt, as evidenced by a low debt-to-equity ratio. However, the company's equity has been decreasing over the years, reflecting financial instability. The return on equity is negative, driven by persistent net losses, which is a major drawback. The equity ratio remains positive but has been declining, showing a weakening financial position.

Cash Flow

Cash flow analysis shows a consistent trend of negative free cash flow, indicating that the company is not generating sufficient cash to cover its operational needs. The operating cash flow to net income ratio is negative, further highlighting cash management issues. Despite occasional inflows from financing activities, the company's cash position has been declining, posing liquidity risks.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	―	―	―	―
	EBIT
-16.00M	-15.37M	-16.38M	-14.91M	-7.73M	-3.60M
	EBITDA
-16.00M	-15.02M	-16.38M	-14.91M	-7.73M	-3.60M
	Net Income Common Stockholders
-15.75M	-15.02M	-15.42M	-13.73M	-7.69M	-3.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.89M	5.79M	13.36M	26.43M	39.13M	1.64M
	Total Assets
5.41M	7.34M	14.92M	28.06M	40.58M	1.78M
	Total Debt
59.51K	84.16K	175.05K	80.49K	169.33K	0.00
	Net Debt
-3.83M	-5.70M	-13.19M	-9.55M	-38.96M	-1.64M
	Total Liabilities
2.61M	3.39M	2.85M	3.43M	4.68M	2.02M
	Stockholders Equity
2.80M	3.94M	12.08M	24.63M	35.90M	-237.70K
Cash Flow		Free Cash Flow
-13.43M	-12.32M	-13.41M	-13.25M	-11.29M	-3.32M
	Operating Cash Flow
-13.43M	-12.32M	-13.41M	-13.08M	-11.29M	-3.32M
	Investing Cash Flow
0.00	0.00	17.14M	-16.43M	447.75K	0.00
	Financing Cash Flow
7.58M	4.75M	0.00	0.00	48.34M	1.16M

Indaptus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDP, the sentiment is Negative. The current price of 0.45 is above the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.56, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 53.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INDP.

Indaptus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	69 Neutral	$12.47M	1.09	7.10%	―	-0.19%	-18.41%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
APLM	42 Neutral	$5.40M	―	-233.67%	―	―	-1786.46%
ACXP	39 Underperform	$9.09M	―	-285.79%	―	―	23.65%
AIMI	36 Underperform	$6.21M	―	-3138.91%	―	-24.35%	60.99%
INDP	27 Underperform	$7.20M	―	-259.00%	―	―	11.97%